// App-Quantinova.ai

PB1451 : FRONT-MIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING EFFICACY AND SAFETY OF R-CHOP + TAFASITAMAB + LENALIDOMIDE VS R-CHOP ALONE FOR NEWLY-DIAGNOSED HIGH-RISK DLBCL

Researchers

Presenter

  • Umberto Vitolo

Principal Investigators

  • Grzegorz S. Nowakowski

  • John M. Burke

  • Christopher P. Fox

  • Marek Trneny

  • Annalisa Chiappella

  • Sascha Tillmanns

  • Andrea Sporchia

  • Wolfram Brugger

  • Georg Lenz

Medical Centers

  • US Oncology Research, Rocky Mountain Cancer Centers,Denver,United States

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Department of Medicine A / Hematology and Oncology, University of Muenster, Muenster, Germany

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Hematology, Mayo Clinic, Rochester, Minnesota, United States

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • MorphoSys AG, Planegg, Germany

Locations

  • United States

  • United Kingdom

  • Germany

  • Czech Republic

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Methotrexate

  • Tafasitamab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02399085

  • NCT04134936

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved